Oncology & Cancer

Marqibo approved for rare leukemia

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philadelphia chromosome negative ...

Medications

Marqibo approved for ph- acute lymphoblastic leukemia

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL).

Oncology & Cancer

Jak of all trades? Not of leukaemia therapy

About one in five or six cases of adult leukaemia in Western populations relates to so-called chronic myeloid leukaemia, or CML. Treatment of CML usually relies on inhibitors of the abnormal protein that causes the condition ...

Oncology & Cancer

Combination therapy for acute lymphoblastic leukemia

A subset of acute lymphoblastic leukemia (ALL) patients is positive for the Philadelphia chromosome, which is generated by a specific translocation event that causes a fusion between the BCR and ABL1 genes. These patients ...

Oncology & Cancer

Anchoring ABL for a better fate

Chronic Myelogenous Leukemia (CML) is a cancer of the white blood cells that is most commonly found in adults and in the elderly. Its incidence has been estimated to be 1 to 2 in 100,000 people. CML was the first cancer to ...

Oncology & Cancer

Gleevec's latest approval is for pediatric cancer

(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...

Oncology & Cancer

Toward a more efficient therapy for a specific form of leukemia

Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius ...

page 2 from 2